Evidence map›Paper›PMID 38384112›Full record

ArticleCurrent medicinal chemistry2024

Synthesis and Selective Anticancer Activity Evaluation of 2-phenylacrylonitrile Derivatives as Tubulin Inhibitors.

Ye-Zhi Jin, Ya-Bing Xin, Yuan Li, Xin-Yuan Chen, De-Ao Man, Yu-Shun Tian

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Current medicinal chemistry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Ye-Zhi JinKey Laboratory of Natural Medicines of the Changbai Mountain, Department of Medicinal Chemistry, Ministry of Education, College of Pharmacy, Yanbian University, Yanji, 133002, Jilin Province, P.R. China.
Ya-Bing XinKey Laboratory of Natural Medicines of the Changbai Mountain, Department of Medicinal Chemistry, Ministry of Education, College of Pharmacy, Yanbian University, Yanji, 133002, Jilin Province, P.R. China.
Yuan LiKey Laboratory of Natural Medicines of the Changbai Mountain, Department of Medicinal Chemistry, Ministry of Education, College of Pharmacy, Yanbian University, Yanji, 133002, Jilin Province, P.R. China.
Xin-Yuan ChenKey Laboratory of Natural Medicines of the Changbai Mountain, Department of Medicinal Chemistry, Ministry of Education, College of Pharmacy, Yanbian University, Yanji, 133002, Jilin Province, P.R. China.
De-Ao ManKey Laboratory of Natural Medicines of the Changbai Mountain, Department of Medicinal Chemistry, Ministry of Education, College of Pharmacy, Yanbian University, Yanji, 133002, Jilin Province, P.R. China.
Yu-Shun TianKey Laboratory of Natural Medicines of the Changbai Mountain, Department of Medicinal Chemistry, Ministry of Education, College of Pharmacy, Yanbian University, Yanji, 133002, Jilin Province, P.R. China.ORCID 0000-0002-9921-9402
Yanbian University · CN

Funding

National Natural Science Foundation of China (NSFC) 81260226
6 · The paper itself

Abstract

objectiveThis study aimed at synthesizing 13 series of novel derivatives with 2-phenylacrylonitrile, evaluating antitumor activity both

methodThe 13 series of 2-phenylacrylonitrile derivatives were synthesized by Knoevenagel condensation and the anti-proliferative activities were determined by MTT assay. The cell cycle and apoptosis were analyzed by flow cytometer. Quantitative cell migration was performed using 24-well Boyden chambers. The proteins were detected by western blotting.

resultsAmong the derivatives, compound 1g2a possessed strong inhibitory activity against HCT116 (IC

conclusionCompound 1g2a shows outstanding antitumor activity both

Indexed as

Antineoplastic AgentsTubulin ModulatorsApoptosisCell Line, TumorCell ProliferationDrug Screening Assays, AntitumorHumansMolecular Docking SimulationStructure-Activity RelationshipTubulinAntineoplastic AgentsTubulinTubulin Modulators2-Phenylacrylonitrileapoptosiscell cycle arrestselective toxic effecttubulin inhibitor.xenograft model

Identifiers

PMID38384112
PMCPMC11071649
OpenAlexW4387770520

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.